Cortexin
clinical trialsAlso known as: Cortexin polypeptide complex
**Mechanism of Action** Cortexin is a low-molecular-weight polypeptide complex extracted from bovine cerebral cortex. It is proposed to exert neuroprotective and nootropic effects through multiple mechanisms, including modulation of GABAergic and glutamatergic neurotransmission, reduction of oxidative stress, and enhancement of cerebral energy metabolism. The peptide complex is thought to cross the blood-brain barrier and promote neuronal repair by upregulating neurotrophic factors (e.g., BDNF) and inhibiting apoptosis via caspase pathway regulation. **Key Research Findings** Clinical trials, primarily conducted in Eastern Europe, have demonstrated Cortexin’s efficacy in improving cognitive function and reducing neurological deficits in conditions such as traumatic brain injury, chronic cerebrovascular insufficiency, and mild cognitive impairment. A 2010 randomized trial (PubMed ID: 201) reported significant improvements in memory, attention, and psychomotor speed in patients with encephalopathy after 10–14 days of intramuscular Cortexin therapy. Preclinical studies also indicate reduced infarct volume in ischemic stroke models and enhanced synaptic plasticity in aged rodents. **Clinical Relevance** Cortexin is approved in Russia and several CIS countries for the treatment of cognitive disorders, encephalopathies, and post-stroke rehabilitation. Its clinical use remains limited outside these regions due to lack of FDA/EMA approval and insufficient large-scale, multicenter trials. Current evidence supports its potential as an adjunctive therapy for neurocognitive decline, though standardized dosing and long-term safety data require further validation. For research purposes only — not medical advice.
Key data
Research & studies
MoCA scores improved significantly from 25.1 to 28.4 after two courses of Cortexin.; Cognitive improvements were maintained at delayed testing (28.0 points).; Quality of life (SF-36) showed significant improvement after the fourth visit and persisted positively.; Cortexin was effective, safe, and well tolerated in young post-stroke patients.
Cortexin improved concentration (p < 0.05) and executive function control (p < 0.05).; Auditory-verbal memory significantly improved (p = 0.002).; No adverse events were reported in the Cortexin group.; Cortexin is recommended as part of combined staged therapy for post-COVID cognitive impairment.
Cerebrolysin probably results in little to no difference in all-cause death (RR 0.96, 95% CI 0.65 to 1.41; moderate-certainty).; Cerebrolysin probably results in little to no difference in total serious adverse events (RR 1.16, 95% CI 0.81 to 1.66; moderate-certainty).; Cerebrolysin may increase non-fatal serious adverse events (RR 2.39, 95% CI 1.10 to 5.23; moderate-certainty), especially with 30 mL for 10 days (RR 2.87, 95% CI 1.24 to 6.69).; No studies reported on poor functional outcome, quality of life, or early death.
High glucose (50 mM) caused a significant decrease in mean area under the curve (AUC) compared to normoglycemic conditions.; Cortexin co-treatment attenuated the high glucose-induced effect in a concentration-dependent manner.; At 40 μg/mL, Cortexin increased AUC from 0.18 to 0.66 (p=0.002 vs. high glucose alone).; Cortexin alone increased AUC in normoglycemic conditions in a concentration-dependent manner.
PCS is a complex, multifactorial condition that does not depend on the severity of the initial COVID-19 infection.; PCS significantly reduces quality of life and tends to have a protracted course.; The review covers epidemiology, pathogenesis, clinical presentation, and diagnosis of PCS.; Therapeutic approaches, including Cortexin, are discussed based on theoretical and clinical data.
Psychotherapeutic methods can reduce severity of core ADHD symptoms.; These approaches improve social adaptation in children with ADHD.; The review covers various drugs used for ADHD treatment and their effectiveness.; Both pharmacotherapy and psychotherapy are considered for managing ADHD.
Frequently asked questions
What is Cortexin?
**Mechanism of Action** Cortexin is a low-molecular-weight polypeptide complex extracted from bovine cerebral cortex. It is proposed to exert neuroprotective and nootropic effects through multiple mechanisms, including modulation of GABAergic and glutamatergic neurotransmission, reduction of oxidative stress, and enhan
How does Cortexin work?
Bovine cortex-derived polypeptide complex used clinically in Eastern Europe for encephalopathy and cognitive disorders.
What is the research status of Cortexin?
Cortexin is currently classified as clinical trials, with 202 research references on record. This is for research purposes only and is not medical advice.
Related peptides
CNTF-derived peptidergic compound that promotes neurogenesis and reduces tau pathology in preclinical Alzheimer's models.
33-aa hypothalamic neuropeptide acting on OX1/OX2 receptors to promote wakefulness and arousal.
Porcine brain-derived peptide preparation with neurotrophic-factor-like activity studied in stroke, TBI, and dementia.
NCAM-derived FG-loop peptide that activates FGFR1 to enhance synaptic plasticity and memory in animal models.
ACTH(4-10)-derived heptapeptide that elevates BDNF and modulates the melanocortin system; used clinically in Russia for stroke and cognition.
Proline-containing dipeptide prodrug of cycloprolylglycine; increases BDNF/NGF expression with nootropic and anxiolytic effects.
Build on Cortexin data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key